The association between lipid metabolism gene polymorphisms and nephropathy in type 2 diabetes: a meta-analysis

International Urology and Nephrology

Volumn 47, Issue 1, 2015, Pages 117-130

  Li, Tingting ^a   Shi, Yun ^a   Yin, Jieyun ^a   Qin, Qin ^a   Wei, Sheng ^a   Nie, Shaofa ^a   Liu, Li ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Acetyl CoA carboxylase ; Apolipoprotein E; Diabetic nephropathy; Meta analysis; Peroxisome proliferator activated receptor ; Polymorphism; Type 2 diabetes

Indexed keywords

ACACB PROTEIN, HUMAN; ACETYL COENZYME A CARBOXYLASE; APOLIPOPROTEIN E; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

COMPLICATION; DIABETIC NEPHROPATHY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HUMAN; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS;

ACETYL-COA CARBOXYLASE; APOLIPOPROTEINS E; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; POLYMORPHISM, GENETIC; PPAR GAMMA;

EID: 84931271683     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-014-0843-6     Document Type: Article

References (52)

1. Macisaac RJ, Ekinci EI, Jerums G (2014) Markers of and risk factors for the development and progression of diabetic kidney disease. Am J Kidney Dis 63(2 Suppl 2):S39–S62
2. Ng MC, Baum L, So WY, Lam VK, Wang Y, Poon E, Tomlinson B, Cheng S, Lindpaintner K, Chan JC (2006) Association of lipoprotein lipase S447X, apolipoprotein E exon 4, and apoC3-455T>C polymorphisms on the susceptibility to diabetic nephropathy. Clin Genet 70(1):20–28
3. Shah VN, Cheema BS, Sharma R, Khullar M, Kohli HS, Ahluwalia TS, Mohan V, Bhansali A (2013) ACACbeta gene (rs2268388) and AGTR1 gene (rs5186) polymorphism and the risk of nephropathy in Asian Indian patients with type 2 diabetes. Mol Cell Biochem 372(1–2):191–198
4. Wu LS, Hsieh CH, Pei D, Hung YJ, Kuo SW, Lin E (2009) Association and interaction analyses of genetic variants in ADIPOQ, ENPP1, GHSR, PPARgamma and TCF7L2 genes for diabetic nephropathy in a Taiwanese population with type 2 diabetes. Nephrol Dial Transplant 24(11):3360–3366
5. Ganan A, Corella D, Guillen M, Ordovas JM, Pocovi M (2004) Frequencies of apolipoprotein A4 gene polymorphisms and association with serum lipid concentrations in two healthy Spanish populations. Hum Biol 76(2):253–266
6. Ha SK, Park HS, Kim KW, Kim SJ, Kim DH, Kim JH, Lee HY, Han DS (1999) Association between apolipoprotein E polymorphism and macroalbuminuria in patients with non-insulin dependent diabetes mellitus. Nephrol Dial Transplant 14(9):2144–2149
7. Hsu CC, Kao WH, Coresh J, Pankow JS, Marsh-Manzi J, Boerwinkle E, Bray MS (2005) Apolipoprotein E and progression of chronic kidney disease. JAMA 293(23):2892–2899
8. Liu L, Xiang K, Zheng T, Zhang R, Li M, Li J (2003) Co-inheritance of specific genotypes of HSPG and ApoE gene increases risk of type 2 diabetic nephropathy. Mol Cell Biochem 254(1–2):353–358
9. Guan J, Zhao HL, Baum L, Sui Y, He L, Wong H, Lai FM, Tong PC, Chan JC (2009) Apolipoprotein E polymorphism and expression in type 2 diabetic patients with nephropathy: clinicopathological correlation. Nephrol Dial Transplant 24(6):1889–1895
10. Kwon MK, Rhee SY, Chon S, Oh S, Woo JT, Kim SW, Kim JW, Kim YS, Jeong KH, Lee SH, Lee TW, Ihm CG (2007) Association between apolipoprotein E genetic polymorphism and the development of diabetic nephropathy in type 2 diabetic patients. Diabetes Res Clin Pract 77(Suppl 1):S228–S232
11. Leiva E, Mujica V, Elematore I, Orrego R, Diaz G, Prieto M, Arredondo M (2007) Relationship between Apolipoprotein E polymorphism and nephropathy in type-2 diabetic patients. Diabetes Res Clin Pract 78(2):196–201
12. Erdogan M, Eroglu Z, Biray C, Karadeniz M, Cetinkalp S, Kosova B, Gunduz C, Topcuoglu N, Ozgen G, Yilmaz C (2009) The relationship of the apolipoprotein E gene polymorphism Turkish Type 2 diabetic patients with and without nephropathy. J Endocrinol Invest 32(3):219–222
13. Ma SW, Benzie IF, Yeung VT (2008) Type 2 diabetes mellitus and its renal complications in relation to apolipoprotein E gene polymorphism. Transl Res 152(3):134–142
14. Tien KJ, Tu ST, Chou CW, Yang CY, Hsiao JY, Shin SJ, Chen HC, Hsieh MC (2011) Apolipoprotein E polymorphism and the progression of diabetic nephropathy in type 2 diabetes. Am J Nephrol 33(3):231–238
15. Willson TM, Lambert MH, Kliewer SA (2001) Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu Rev Biochem 70:341–367
16. Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, Nemesh J, Lane CR, Schaffner SF, Bolk S, Brewer C, Tuomi T, Gaudet D, Hudson TJ, Daly M, Groop L, Lander ES (2000) The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 26(1):76–80
17. Herrmann SM, Ringel J, Wang JG, Staessen JA, Brand E (2002) Peroxisome proliferator-activated receptor-gamma2 polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes: the Berlin Diabetes Mellitus (BeDiaM) Study. Diabetes 51(8):2653–2657
18. Caramori ML, Canani LH, Costa LA, Gross JL (2003) The human peroxisome proliferator-activated receptor gamma2 (PPARgamma2) Pro12Ala polymorphism is associated with decreased risk of diabetic nephropathy in patients with type 2 diabetes. Diabetes 52(12):3010–3013
19. Liu L, Zheng T, Wang F, Wang N, Song Y, Li M, Li L, Jiang J, Zhao W (2010) Pro12Ala polymorphism in the PPARG gene contributes to the development of diabetic nephropathy in Chinese type 2 diabetic patients. Diabetes Care 33(1):144–149
20. De Cosmo S, Prudente S, Lamacchia O, Lapice E, Morini E, Di Paola R, Copetti M, Ruggenenti P, Remuzzi G, Vaccaro O, Cignarelli M, Trischitta V (2011) PPARgamma2 P12A polymorphism and albuminuria in patients with type 2 diabetes: a meta-analysis of case-control studies. Nephrol Dial Transplant 26(12):4011–4016
21. Stefanski A, Majkowska L, Ciechanowicz A, Frankow M, Safranow K, Parczewski M, Pilarska K (2006) Lack of association between the Pro12Ala polymorphism in PPAR-gamma2 gene and body weight changes, insulin resistance and chronic diabetic complications in obese patients with type 2 diabetes. Arch Med Res 37(6):736–743
22. Erdogan M, Karadeniz M, Eroglu Z, Tezcanli B, Selvi N, Yilmaz C (2007) The relationship of the peroxisome proliferator-activated receptor-gamma 2 exon 2 and exon 6 gene polymorphism in Turkish type 2 diabetic patients with and without nephropathy. Diabetes Res Clin Pract 78(3):355–359
23. Bhaskar LV, Mahin S, Ginila RT, Soundararajan P (2013) Role of the ACE ID and PPARG P12A polymorphisms in genetic susceptibility of diabetic nephropathy in a south indian population. Nephrourol Mon 5(3):813–817
24. Ma L, Mondal AK, Murea M, Sharma NK, Tonjes A, Langberg KA, Das SK, Franks PW, Kovacs P, Antinozzi PA, Stumvoll M, Parks JS, Elbein SC, Freedman BI (2011) The effect of ACACB cis-variants on gene expression and metabolic traits. PLoS ONE 6(8):e23860
25. Maeda S, Kobayashi MA, Araki S, Babazono T, Freedman BI, Bostrom MA, Cooke JN, Toyoda M, Umezono T, Tarnow L, Hansen T, Gaede P, Jorsal A, Ng DP, Ikeda M, Yanagimoto T, Tsunoda T, Unoki H, Kawai K, Imanishi M, Suzuki D, Shin HD, Park KS, Kashiwagi A, Iwamoto Y, Kaku K, Kawamori R, Parving HH, Bowden DW, Pedersen O, Nakamura Y (2010) A single nucleotide polymorphism within the acetyl-coenzyme A carboxylase beta gene is associated with proteinuria in patients with type 2 diabetes. PLoS Genet 6(2):e1000842
26. Tang SC, Leung VT, Chan LY, Wong SS, Chu DW, Leung JC, Ho YW, Lai KN, Ma L, Elbein SC, Bowden DW, Hicks PJ, Comeau ME, Langefeld CD, Freedman BI (2010) The acetyl-coenzyme A carboxylase beta (ACACB) gene is associated with nephropathy in Chinese patients with type 2 diabetes. Nephrol Dial Transplant 25(12):3931–3934
27. Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25(9):603–605
28. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557–560
29. Wigginton JE, Cutler DJ, Abecasis GR (2005) A note on exact tests of Hardy-Weinberg equilibrium. Am J Hum Genet 76(5):887–893
30. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4):1088–1101
31. Araki S, Koya D, Makiishi T, Sugimoto T, Isono M, Kikkawa R, Kashiwagi A, Haneda M (2003) APOE polymorphism and the progression of diabetic nephropathy in Japanese subjects with type 2 diabetes: results of a prospective observational follow-up study. Diabetes Care 26(8):2416–2420
32. Reis KA, Ebinc FA, Koc E, Demirci H, Erten Y, Guz G, Derici UB, Bali M, Soylemezoglu O, Arinsoy T, Sindel S (2011) Association of the angiotensinogen M235T and APO E gene polymorphisms in Turkish type 2 diabetic patients with and without nephropathy. Ren Fail 33(5):469–474
33. Ilhan N, Kahraman N, Seckin D, Colak R (2007) Apo E gene polymorphism on development of diabetic nephropathy. Cell Biochem Funct 25(5):527–532
34. Hsieh MC, Lin SR, Yang YC, Chen HC, Lin JN, Shin SJ (2002) Higher frequency of apolipoprotein E2 allele in type 2 diabetic patients with nephropathy in Taiwan. J Nephrol 15(4):368–373
35. Akarsu E, Pirim I, Capoglu I, Kaya H, Akcak G, Unuvar N (2001) A relation between the apolipoprotein E genotypes and microalbuminuria in type 2 diabetes mellitus. Turk J Med Sci 31:59–64
36. Kimura H, Suzuki Y, Gejyo F, Karasawa R, Miyazaki R, Suzuki S, Arakawa M (1998) Apolipoprotein E4 reduces risk of diabetic nephropathy in patients with NIDDM. Am J Kidney Dis 31(4):666–673
37. Eto M, Horita K, Morikawa A, Nakata H, Okada M, Saito M, Nomura M, Abiko A, Iwashima Y, Ikoda A et al (1995) Increased frequency of apolipoprotein epsilon 2 allele in non-insulin dependent diabetic (NIDDM) patients with nephropathy. Clin Genet 48(6):288–292
38. Zhang H, Zhu S, Chen J, Tang Y, Hu H, Mohan V, Venkatesan R, Wang J, Chen H (2012) Peroxisome proliferator–activated receptor gamma polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes: evidence from meta-analysis of 18 studies. Diabetes Care 35(6):1388–1393
39. Lapice E, Pinelli M, Riccardi G, Vaccaro O (2010) Pro12Ala polymorphism in the PPARG gene contributes to the development of diabetic nephropathy in Chinese type 2 diabetic patients: comment on the study by Liu et al. Diabetes Care 33 (8):e114; author reply e115
40. De Cosmo S, Motterlini N, Prudente S, Pellegrini F, Trevisan R, Bossi A, Remuzzi G, Trischitta V, Ruggenenti P (2009) Impact of the PPAR-gamma2 Pro12Ala polymorphism and ACE inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: evidence from BENEDICT. Diabetes 58(12):2920–2929
41. Pollex RL, Mamakeesick M, Zinman B, Harris SB, Hegele RA, Hanley AJ (2007) Peroxisome proliferator-activated receptor gamma polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes. J Diabetes Complications 21(3):166–171
42. Mori H, Ikegami H, Kawaguchi Y, Seino S, Yokoi N, Takeda J, Inoue I, Seino Y, Yasuda K, Hanafusa T, Yamagata K, Awata T, Kadowaki T, Hara K, Yamada N, Gotoda T, Iwasaki N, Iwamoto Y, Sanke T, Nanjo K, Oka Y, Matsutani A, Maeda E, Kasuga M (2001) The Pro12 –>Ala substitution in PPAR-gamma is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. Diabetes 50(4):891–894
43. Horita K, Eto M, Makino I (1994) Apolipoprotein E2, renal failure and lipid abnormalities in non-insulin-dependent diabetes mellitus. Atherosclerosis 107(2):203–211
44. Maeda A, Gohda T, Funabiki K, Horikoshi S, Tomino Y (2004) Peroxisome proliferator-activated receptor gamma gene polymorphism is associated with serum triglyceride levels and body mass index in Japanese type 2 diabetic patients. J Clin Lab Anal 18(6):317–321
45. Buzello M, Tornig J, Faulhaber J, Ehmke H, Ritz E, Amann K (2003) The apolipoprotein e knockout mouse: a model documenting accelerated atherogenesis in uremia. J Am Soc Nephrol 14(2):311–316
46. Li Y, Tang K, Zhang Z, Zhang M, Zeng Z, He Z, He L, Wan C (2011) Genetic diversity of the apolipoprotein E gene and diabetic nephropathy: a meta-analysis. Mol Biol Rep 38(5):3243–3252
47. Mooyaart AL, Valk EJ, van Es LA, Bruijn JA, de Heer E, Freedman BI, Dekkers OM, Baelde HJ (2011) Genetic associations in diabetic nephropathy: a meta-analysis. Diabetologia 54(3):544–553
48. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, Laakso M, Fujimoto W, Auwerx J (1998) A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 20(3):284–287
49. Jia Z, Sun Y, Yang G, Zhang A, Huang S, Heiney KM, Zhang Y (2014) New Insights into the PPAR Agonists for the treatment of diabetic nephropathy. PPAR Res 2014:818530
50. Wahba IM, Mak RH (2007) Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney disease. Clin J Am Soc Nephrol 2(3):550–562
51. Jiang T, Wang Z, Proctor G, Moskowitz S, Liebman SE, Rogers T, Lucia MS, Li J, Levi M (2005) Diet-induced obesity in C57BL/6 J mice causes increased renal lipid accumulation and glomerulosclerosis via a sterol regulatory element-binding protein-1c-dependent pathway. J Biol Chem 280(37):32317–32325
52. Wang Z, Jiang T, Li J, Proctor G, McManaman JL, Lucia S, Chua S, Levi M (2005) Regulation of renal lipid metabolism, lipid accumulation, and glomerulosclerosis in FVBdb/db mice with type 2 diabetes. Diabetes 54(8):2328–2335